Stability of Rivaroxaban and Apixaban Anti-Xa Activities in Whole Blood Samples: A French Bicentric Study

Alexandre Raynor; Klara Lunte; Mayssa Gaaloul; Amandine Caillault; Fouzia Zouiti; Céline Desconclois; Virginie Planche

doi:10.1055/s-0043-1763254

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2023; 123(05): 565-567
DOI: 10.1055/s-0043-1763254

Letter to the Editor

Stability of Rivaroxaban and Apixaban Anti-Xa Activities in Whole Blood Samples: A French Bicentric Study

Alexandre Raynor

¹Service d'hématologie Biologique, Hôpital Antoine-Béclère, Clamart, France

,

Klara Lunte

²Service d'hématologie Biologique, Hôpital Saint-Antoine, Paris, France

,

Mayssa Gaaloul

¹Service d'hématologie Biologique, Hôpital Antoine-Béclère, Clamart, France

,

Amandine Caillault

¹Service d'hématologie Biologique, Hôpital Antoine-Béclère, Clamart, France

,

Fouzia Zouiti

¹Service d'hématologie Biologique, Hôpital Antoine-Béclère, Clamart, France

,

Céline Desconclois

¹Service d'hématologie Biologique, Hôpital Antoine-Béclère, Clamart, France

,

Virginie Planche

²Service d'hématologie Biologique, Hôpital Saint-Antoine, Paris, France

References
1 Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet 2020; 396 (10264): 1767-1776
2 Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19 (08) 1874-1882
3 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
4 Kitchen S, Gray E, Mackie I, Baglin T, Makris M. BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 2014; 166 (06) 830-841
5 Douxfils J, Adcock DM, Bates SM. et al. 2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2021; 121 (08) 1008-1020
6 Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature. Eur J Haematol 2019; 102 (04) 312-318
7 Groupe d'études sur l'Hémostase et la Thrombose (GFHT). [Recommandations pré-analytiques en hémostase: Stabilité des paramètres d'hémostase spécialisée et délais de réalisation des examens (partie 2)] [Internet]. [Paris]: GFHT; 2018 [cited 2022 Jul 29]. Available at: https://site.geht.org/
8 Gosselin RC, Adcock DM, Bates SM. et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
9 McGrail R, Revsholm J, Nissen PH, Grove EL, Hvas AM. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res 2016; 148: 107-110
10 Boissier E, Genebrier S, Lakhal K. et al. Rivaroxaban and apixaban anti-Xa measurements: impact of plasma storage for 7 days at room temperature. Thromb Haemost 2018; 118 (08) 1488-1490
11 Godier A, Dincq AS, Martin AC. et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38 (31) 2431-2439
12 Thuile K, Giacomuzzi K, Jani E, Marschang P, Mueller T. Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions. Scand J Clin Lab Invest 2021; 81 (06) 461-468